title: Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma.
abstract: OBJECTIVE
  The current standard local treatment for nonresectable pancreatic carcinoma is radiotherapy (RT) with concurrent 5-fluorouracil (5-FU); however, the optimal schedule for 5-FU administration has not been fully established. In this study, we report on our experience with the combination of RT and continuous infusion 5-FU in a group of patients with locally nonresectable pancreatic carcinoma.
  
  
  METHODS
  Forty-two patients with adenocarcinoma of the pancreas were enrolled in a prospective clinical trial. RT was delivered using a four-field technique to a total dose of 59.4 Gy in 33 fractions. 5-FU was given through a central venous catheter at a dose of 300 mg/m(2)/day, 7 d/wk, throughout the entire course of RT.
  
  
  RESULTS
  All patients completed the RT as planned, and 33 (78%) completed the full regimen of chemotherapy. Ten patients (23%) had a partial response, and 32 (77%) had stable disease. Subjective response, defined as the disappearance of symptoms observed at diagnosis, was also evaluated. Two patients (6%) had a complete, and 24 (75%) a partial, remission of symptoms. The median time to progression was 6.2 months, and the median survival time was 9.1 months.
  
  
  CONCLUSIONS
  In terms of local control, the results of our study, with RT and protracted 5-FU infusion, compare well with those of other studies using RT and bolus 5-FU. The control of distant metastatic disease remains an open issue. However, the palliation of symptoms achieved by our treatment schedule in patients with a very poor prognosis and severe symptoms may be regarded as a positive result.
authors.affiliation: Department of Radiotherapy, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy. staff@radioterapiacro.it
authors.forename: G
authors.initials: G
authors.lastname: Boz
authors.forename: A
authors.initials: A
authors.lastname: De Paoli
authors.forename: R
authors.initials: R
authors.lastname: Innocente
authors.forename: C
authors.initials: C
authors.lastname: Rossi
authors.forename: G
authors.initials: G
authors.lastname: Tosolini
authors.forename: P
authors.initials: P
authors.lastname: Pederzoli
authors.forename: R
authors.initials: R
authors.lastname: Talamini
authors.forename: M G
authors.initials: MG
authors.lastname: Trovò
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D011446:Prospective Studies; D011879:Radiotherapy Dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil